A paradigm shift in the treatment of advanced non-small cell lung cancer

Shibu Varughese, K. Saad Jahangir, Catherine E. Simpson, Brian C. Boulmay

Research output: Contribution to journalArticlepeer-review

Abstract

Lung cancer is the most common cause of cancer death for men and women worldwide. Nonsmall cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Systemic chemotherapy is a cornerstone of treatment in the management of stage IV NSCLC. First-line chemotherapy typically consists of a platinum-based treatment. The optimum approach to long-term treatment beyond 4 to 6 cycles of chemotherapy is still evolving. Second-line chemotherapy given at the time of disease progression has shown clear survival advantages when compared with best supportive care alone. With the recent increase in the number of active and more tolerable agents available to treat NSCLC, there is renewed interest in the role of continuation of antineoplastic agents (continuation maintenance) or switching to a different agent (switch maintenance) after first-line chemotherapy. This case-based review discusses the role of maintenance chemotherapy in the long-term management of advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)147-150
Number of pages4
JournalAmerican Journal of the Medical Sciences
Volume344
Issue number2
DOIs
StatePublished - Aug 2012

Keywords

  • Chemotherapy
  • Lung cancer
  • Maintenance chemotherapy
  • NSCLC
  • Platinum-based

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A paradigm shift in the treatment of advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this